On April 20, 2018 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, reported the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $7.50 per share (Press release, Bellicum Pharmaceuticals, APR 20, 2018, View Source [SID1234525576]). The aggregate offering size was $69.0 million, before deducting the underwriting discounts and commissions and other offering expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citigroup and Jefferies acted as lead book-running managers for the offering. Guggenheim Securities, Ladenburg Thalmann and Raymond James acted as co-managers.